Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTT-015
- Development stage
- Preclinical
- Lead developer
- Pyrotech Therapeutics
01
Overview
PTT-015 is an investigational drug candidate currently in the early discovery stage, developed by Pyrotech Therapeutics for the treatment of autoimmune diseases. Pyrotech Therapeutics is a biotechnology company that specializes in the biology of pyroptosis—a highly inflammatory form of programmed cell death—to develop novel therapies for inflammatory, autoimmune, and oncology indications. While the specific molecular target and modality of PTT-015 have not been publicly disclosed, the asset is part of a broader pipeline aimed at modulating pro-inflammatory signaling pathways to address unmet medical needs in immunology.
Beyond the preview
Go deeper on PTT-015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTT-015.